PCA3 and prostate cancer: We propose multiplexing this assay with our previously identified aggressive disease markers, as well as existing clinical biomarkers such as Prostate cancer antigen 3 (PCA3), TMPRSS2:ERG (T2:ERG), etc. to assist in the management of prostate cancer especially in low‐risk cohorts.